C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 7/04 (2006.01) A61K 31/7088 (2006.01) A61K 39/285 (2006.01) A61K 45/08 (2006.01) A61K 48/00 (2006.01) C12N 5/10 (2006.01) C12N 15/39 (2006.01) C12N 15/863 (2006.01) C12P 21/00 (2006.01)
Patent
CA 2421151
The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and which is characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus or its recombinants as medicament or vaccine. Additionally, a method for inducing an immune response even in immuno-compromised patients, patients with pre-existing immunity to the vaccine virus or patients undergoing antiviral therapies is provided.
L'invention concerne un virus atténué dérivé du virus de la vaccine MVA (Modified Vaccinia Ankara), caractérisé par la perte de son aptitude à se répliquer de manière reproductive dans des lignées cellulaires humaines. L'invention concerne également des virus de recombinaison dérivés dudit virus, et l'utilisation de ce virus ou de ses recombinants comme médicament ou vaccin. L'invention concerne enfin une méthode permettant d'induire une réponse immunitaire même chez des patients à immunité compromise, chez des patients à immunité préexistante contre le virus de la vaccine, ou chez des patients ayant commencé des thérapies antivirales.
Chaplin Paul
Howley Paul
Meisinger Christine
Bavarian Nordic A/s
Smart & Biggar
LandOfFree
Modified vaccinia ankara virus variant does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified vaccinia ankara virus variant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified vaccinia ankara virus variant will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1400982